| 0.2258 0.003 (1.3%) | 04-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.43 | 1-year : | 0.59 |
| Resists | First : | 0.37 | Second : | 0.5 |
| Pivot price | 0.18 |
|||
| Supports | First : | 0.14 | Second : | 0.12 |
| MAs | MA(5) : | 0.2  |
MA(20) : | 0.2 |
| MA(100) : | 0.49 |
MA(250) : | 3.68 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 73.1 |
D(3) : | 56.4 |
| RSI | RSI(14): 46.9 |
|||
| 52-week | High : | 20.6 | Low : | 0.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ KALA ] has closed below upper band by 6.5%. Bollinger Bands are 69.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.23 - 0.23 | 0.23 - 0.23 |
| Low: | 0.21 - 0.21 | 0.21 - 0.21 |
| Close: | 0.22 - 0.23 | 0.23 - 0.23 |
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Wed, 01 Apr 2026
Kala Bio engages advisor to review clinical assets, AI analytics - Investing.com
Mon, 30 Mar 2026
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch - Kala Bio (NASDAQ:K - Benzinga
Fri, 27 Mar 2026
KALA BIO Inc expected to post a loss of $1.44 a share - Earnings Preview - TradingView — Track All Markets
Sun, 22 Mar 2026
If You Invested $1,000 in Kala Pharmaceuticals Inc (KALA) - Stock Titan
Tue, 17 Mar 2026
[144] KALA BIO, Inc. SEC Filing - Stock Titan
Wed, 11 Mar 2026
$180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 911 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 6,830 (K) |
| Shares Short P.Month | 657 (K) |
| EPS | -5.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -65.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.05 |
| PEG Ratio | 0 |
| Price to Book value | -0.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|